Home » LUNDBECK BEGINS PHASE I TRIAL OF LU AA34893 FOR DEPRESSION
LUNDBECK BEGINS PHASE I TRIAL OF LU AA34893 FOR DEPRESSION
Lundbeck has initiated Phase I clinical trials with its pharmaceutical candidate Lu AA34893 to investigate the tolerability and pharmacokinetic profile of the compound in humans as a treatment for depression.
Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of depression and anxiety disorders.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May